Thus, inhibition of HSP90 destabilizes client proteins such as AKT and 3-phosphoinositide-dependent protein kinase-1 (PDK1)18, disrupting PAM signaling and sensitizing tumor cells to apoptosis. Here, HSP90AB1 is linked to neoplasm.